Zinc Therapy in Wilson's Disease: Observations in Five Patients

Rossaro, Lorenzo; Sturniolo, Giacomo Carlo; Giacon, Gabriella; Montino, Maria Cristina; Lecis, Pier Enrico; Schade, Robert R.; Corazza, Gino R.; Trevisan, Carlo; Naccarato, Remo
June 1990
American Journal of Gastroenterology;Jun1990, Vol. 85 Issue 6, p665
Academic Journal
We report our experience with zinc (Zn) therapy in five patients with Wilson's disease (WD). In addition to neurologic examination, evaluation of Kayser-Fleischer rings and liver function tests, copper (Cu) and Zn concentrations in liver tissue, plasma, and urine were periodically evaluated by spectrophotometry. Many of the patients had had side effects due to penicillamine (PCA). Oral Zn sulphate (220 mg tid) reduced the WD symptoms and resulted in normal urinary Cu excretion in all five patients. One patient who had a transient gastric complaint during Zn administration, and in whom a decrease in liver Cu content was not observed, did not show any improvement in liver histology. He resumed PCA therapy after 29 months of Zn therapy. We conclude that long-term Zn treatment in Wilson's disease can be a safe and effective alternative to Cu chelating agents. However, patients should be periodically monitored for their Cu/Zn status to assess patient compliance with therapy.


Related Articles

  • Oral Zinc Therapy for Wilson's Disease. Brewer, George J.; Hill, Gretchen M.; Prasad, Ananda S.; Cossack, Zafrallah T.; Rabbani, Parviz // Annals of Internal Medicine;Sep83, Vol. 99 Issue 3, p314 

    Presents information on a study which assessed the efficacy of zinc treatment in patients with Wilson's disease. Methodology of the study; Results and discussion.

  • Wilson disease: a most unusual patient. Walshe, J. M. // QJM: An International Journal of Medicine;Feb2016, Vol. 109 Issue 2, p117 

    No abstract available.

  • Quality of life in Wilson's disease. Kumar, R. N. Komal; Taly, A. B.; Nair, K. P. S.; Sinha, S.; Prashanth, L. K.; Vidya, N.; Arunodaya, G. R.; Rao, S. // Annals of Indian Academy of Neurology;Jan2008, Vol. 11 Issue 1, p37 

    Background: Assessment of Quality of life (QoL) is fast assuming significance as the measure of health in many disorders. Aim: To correlate clinical severity and QoL in patients with Wilson's disease (WD). Materials and Methods: We evaluated patients of WD on regular follow up for at least two...

  • Mechanisms of Pennicillamine and Zinc in the Treatment of Wilson's Disease. Farinati, F.; Cardin, R.; Mestriner, C.; Sturniolo, G. C.; Naecarato, R. // American Journal of Gastroenterology;Dec1995, Vol. 90 Issue 12, p2264 

    Presents letters to the editor referencing articles and topics discussed in previous issues. "Penicillamine Hypersensitivity: Successful Desensitization of Patients With Severe Hepatic Wilson's Disease," which examined hepatic Wilson's disease; "The Mechanisms of Penicillamine, Trientine, and...

  • A severe case of esophageal ulcer causing a tight stricture despite long-term D-penicillamine treatment. Yapali, Suna; Turan, Ilker; Ozutemiz, Omer; Tekesin, Oktay // Wiener Klinische Wochenschrift;Dec2014, Vol. 126 Issue 23/24, p789 

    D-penicillamine has long been used in the management of rheumatic diseases due to the effects on inhibition of collagen synthesis. Herein, we report a severe case of esophageal ulcer causing a tight stricture extending through the distal esophagus despite the long-term D-penicillamine treatment...

  • Phenotype-Genotype Correlation in Wilson Disease in a Large Lebanese Family: Association of c.2299insC with Hepatic and of p. Ala1003Thr with Neurologic Phenotype. Usta, Julnar; Wehbeh, Antonios; Rida, Khaled; El-Rifai, Omar; Estiphan, Theresa Alicia; Majarian, Tamar; Barada, Kassem // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Genotype phenotype correlations in Wilson disease (WD) are best established in homozygous patients or in compound heterozygous patients carrying the same set of mutations. We determined the clinical phenotype of patients with WD carrying the c.2298_2299insC in Exon 8 (c.2299insC) or the p....

  • ZINC THERAPY INDUCTION OF INTESTINAL METALLOTHIONEIN IN WILSON'S DISEASE. Brewer, George J. // American Journal of Gastroenterology;Feb1999, Vol. 94 Issue 2, p301 

    Examines the efficacy of zinc in the treatment of Wilson's disease. Anticopper agent that can be used in the treatment of Wilson's disease; Link between zinc therapy and metallothionein levels in patients with Wilson's disease; Effectiveness of zinc, penicillamine and trietine in maintaining a...

  • Effective treatment of Wilson's disease with oral zinc sulphate: two cases reported. Hoogenraad, Tjaard U.; Van Den Hamer, Cornelis J.A.; Van Hattum, Jan // British Medical Journal (Clinical Research Edition);8/4/1984, Vol. 289 Issue 6440, p273 

    Evaluates the efficacy of oral zinc sulphate in the treatment of Wilson's disease. Assessment on the toxicity of zinc; Administration of zinc sulphate in patients with severe neurological symptoms; Adoption of intravenous radiocopper loading test and liver biopsy.

  • NOT A NEW THYROID SYNDROME. Long, Howard; O'Connor, Patrick G. // Cortlandt Forum;12/20/2001, Vol. 14 Issue 12, p62 

    Presents a letter on the incidence of Wilson's syndrome in the United States. Symptoms of the disease; Efficacy of thyroid USP; Occurrence of deiodinase deficiency in affected patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics